Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ: OCGN )

0.7980 +0.0780 (+10.83%)
Streaming Delayed Price Updated: 1:52 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
33 34 Next >
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
From Ocugen
Via GlobeNewswire
Ocugen to Present at BIO International Convention 2023
From Ocugen
Via GlobeNewswire
Ocugen (OCGN) Q1 2023 Earnings Call Transcript
OCGN earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Ocugen: Q1 Earnings Insights
Via Benzinga
Ocugen Provides Business Update with First Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
Earnings Outlook For Ocugen
Via Benzinga
Analyst Ratings for Ocugen
Via Benzinga
Ocugen Highlights Interim Data From Gene Therapy Study For Genetic Vision Loss Disorder
Via Benzinga
Earnings Scheduled For May 5, 2023
Companies Reporting Before The Bell • CNH Industrial (NYSE:CNHI) is estimated to report quarterly earnings at $0.32 per share on revenue of $5.08 billion. 
Via Benzinga
Why Ocugen Stock Eked Out a Win Today
The company is clearly progressing on several fronts with its pipeline programs. 
Via The Motley Fool
Ocugen (OCGN) Q4 2022 Earnings Call Transcript
OCGN earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies
U.S. Food & Drug Administration (FDA) grants orphan drug designation to OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt, RP19 and CORD3 
From Ocugen
Via GlobeNewswire
Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
From Ocugen
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's session saw 286 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 147 stocks made new 52-week lows. 
Via Benzinga
Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting
From Ocugen
Via GlobeNewswire
GETY Stock Alert: Trillium Capital Wants a Seat on Getty Images’ Board
Getty Images (GETY) stock is on the rise Friday as investors take note of Trillium Capital seeking a seat on the company's Board. 
Via InvestorPlace
SOFI Stock Pops as Bank Stocks Gain
SoFi Technologies (SOFI) stock is on the rise Friday as the company's shares rally alongside other shares in the financial sector. 
Via InvestorPlace
Why Are Bank Stocks JPM, WFC, PNC On The Move Today?
Bank stocks are on the move Friday after several big companies in the sector released positive earnings reports this morning. 
Via InvestorPlace
Why Is Ocugen (OCGN) Stock Moving Today?
Ocugen (OCGN) stock is on the move Friday after the company revealed preliminary results from an ongoing clinical trial. 
Via InvestorPlace
Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis
From Ocugen
Via GlobeNewswire
Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023
Company to share preliminary safety and efficacy data from ongoing Phase 1/2 trial of OCU400 for the treatment of retinitis pigmentosa and Leber congenital amaurosis 
From Ocugen
Via GlobeNewswire
Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress
From Ocugen
Via GlobeNewswire
Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
From Ocugen
Via GlobeNewswire
Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference
From Ocugen
Via GlobeNewswire
Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer
From Ocugen
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
Via Benzinga
Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket
Gainers Catalyst Biosciences Inc (NASDAQ: CBIO) rose 105% to $0.49 in pre-market trading. South Korea's GC Biopharma said it has signed an asset purchase agreement with Catalyst Biosciences to acquire... 
Via Benzinga
Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results
From Ocugen
Via GlobeNewswire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.